CLOs on the Move

ZS Pharma

www.zspharma.com

 
ZS Pharma is using innovative technology to change the landscape of disease management. At ZS Pharma, we have a vision—to transform the status quo and improve the options for patients and physicians facing difficult-to-manage conditions such as ion imbalances. We are committed to taking on medicine’s challenges with a new outlook, and we believe that real progress comes with a real promise to approach things in a novel way.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.zspharma.com
  • 805 Veterans Blvd. Suite 300
    Redwood City, CA USA 94063
  • Phone: 765.742.4813

Executives

Name Title Contact Details

Similar Companies

GenPrime

GenPrime is a Spokane, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ascus Biosciences

The mission at Ascus Biosciences is better microbes for a better life. Based in San Diego, CA, Ascus is focused on discovering, developing, and commercializing first-in-class endomicrobial products for the animal health and nutrition industries.

Abnova Corporation

Abnova Corporation is a Walnut, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Innopsys

Innopsys is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vaxart

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.